Prevalens, viral load and types diversity of high-risk HPV in patients with infl ammatory and tumor diseases

Objective: analysis of the type-specific prevalence of high-risk HPV in dependence on gender, age, the presence of cancer. Material and methods: 424 patients of the RRIO were examined. Urogenital smears in women and in men, urine in men were tested for HPV DNA using PCR. Results: The relative share of HPV-positive patients was 34.4% in women and 39.9% in men. The percentage of HPV-positive patients decreased in older women and increased in men. HPV was registered more oft en in women younger than 25 and older than 45 years old and in men aged 26-45 years. Multiple-type HPV infection was registered more oft en in young patients. HPV 16 was the most prevalent in men and women; next most prevalent types were HPV 31, 52, 18 and 56 in women and HPV 52, 56, 45 and 18 in men. HPV 51 was found in women only. HPV infections were registered in cancer patients 1.9 times more oft en than in patients with inflammatory diseases. A high viral load prevailed in women with cancer; viral load with varying clinical significance was equally frequent in patients with inflammatory diseases. Combinations of simultaneous infection with HPV and STI agents in women with cancer amounted to 70.6% of the total number of STI-positive patients and 41.5% in women with inflammatory diseases, in men – 66.7% and 38.1%, respectively. Conclusions: The obtained results allowed to reveal gender and age differences in the HPV prevalence in dependence on gender, age and the presence of cancer.

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210

2. Arkhipova OE, Chernogubova EA, Likhtanskaya NV, Tarasov VA, Kit OI, Matishov DG. Analysis of occurrence of on-cological diseases in the Rostov Region. Spatial-time statistic. Fundamental research. 2013;(7):504-510 (in Russ.)

3. Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’). Moscow; 2017. (in Russ.)

4. Aksel’ EM. Statistics of malignant tumors of female reproductive system. Onkoginekologiya. 2012;(1):18-23. (in Russ.)

5. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609-16. doi: 10.1016/S2214-109X(16)30143-7

6. Kostin AA, Starinskiy VV, Samsonov YV, Asratov AT. Th e analysis of statistical data on malignant neoplasms associated with human P apillomavirus. Research’n Practical Medicine Journal. 2016;3(1):66-78. (In Russ.) DOI:10.17709/2409-2231-2016-3-1-9

7. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings. J Infect Dis. 2010;202(12):1789-99. doi: 10.1086/657321

8. Shipulina OYu. Epidemiologicheskie osobennosti i mery pro-fi laktiki onkoginekologicheskoi patologii papillomavirusnoi etiologii: avtoreferat dis. … kand. med. nauk: Moskva; 2013. (in Russ.)

9. Rogovskaya SI Mikheeva IV, Shipulina OYu, Minkina GN, Podzolkova NM, et al. Prevalence of Human Papillomavirus Infection in Russia. Epidemiologiya i Vaktsinoprofi laktika. 2012;62(1):25-33. (in Russ.)

10. Chulkova OV, Novikova EG, Sokolov VV. Diagnostika i lechenie fonovykh i predrakovykh zabolevanii vul’vy. Prakticheskaya onkologiya. 2006;7(4):197-204. (in Russ.)

11. Vergeichik G.I. Diagnostics and treatment of anogenital zone lesions aroused with human papillomavirus infection. Meditsinskie novosti. 2012;(12):68-71. (in Russ.)

12. Orekhov DV, Skidan NI, Evstigneeva NP, Kuznetsova YuN. Papillomavirusnaya infektsiya urogenital’nogo trakta u mu-zhchin reproduktivnogo vozrasta. Dermatovenerologiya. 2011;8(86):80-83. (in Russ.)

13. Unanyan AL, Kossovich YuM. Chronic cervicitis: specifi c features of its etiology, pathogenesis, diagnosis, and treatment. Ros. vestn. akushera-ginekologa. 2012;(6):40-45. (in Russ.)

14. Mal’tseva LI, Farrakhova LN. Treatment of HPV-associated cervicitis. Eff ektivnaya farmakoterapiya. 2013;(8):42-48. (in Russ.)

15. Varegina IZ, Zykova TA. Pokazateli shirokogo spektra genotipirovaniya virusov papillomy cheloveka vysokogo kantserogennogo riska. Aktual’nye problemy deyatel’nosti konsul’tativno-diagnosticheskikh tsentrov. Materialy ezhegodnoi konferentsii DiaMA. 2011:53-54. (in Russ.)